Overview

A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).
Phase:
Phase 1
Details
Lead Sponsor:
KoBioLabs
Collaborator:
Novotech (Australia) Pty Limited